Added to YB: 2025-01-23
Pitch date: 2025-01-23
KROS [bullish]
Keros Therapeutics, Inc.
+76.33%
current return
Author Info
No bio for this author
Company Info
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
Market Cap
$525.8M
Pitch Price
$12.04
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.82
P/E
10.96
EV/Sales
-0.61
Sector
Biotechnology
Category
value
Keros Therapeutics (KROS): Undervalued Opportunity with Strong Cash Position and Strategic Partnerships
KROS: Net cash ~$18/share by Mar 2025. Undervalued considering Takeda deal (elritercept), reduced burn, potential ATM in Q4. NPV of elritercept milestones/royalties & KER-065 add value. Experienced dealmaker mgmt (ex-Acceleron). Massive discount likely to narrow.
Read full article (1 min)